财务数据关键指标变化 - 2024年底现金、现金等价物和短期投资总计1.52114亿美元，预计运营资金可维持到2027年[1][9][13] - 2024年第四季度研发费用为1331.4万美元，全年为5526.7万美元，2023年同期分别为1041.4万美元和4263.7万美元[9][13] - 2024年第四季度一般及行政费用为496.4万美元，全年为1800万美元，2023年同期分别为338.2万美元和1215.9万美元[9][13] - 2024年第四季度净亏损为1644.8万美元，全年为6536.3万美元，2023年同期分别为1214.4万美元和4943.4万美元[9][13] - 2024年底总资产为2.06409亿美元，总负债为5576.7万美元[13] - 2024年底股东权益总额为1.50642亿美元[13] 业务项目进展 - BBI - 355的1/2期POTENTIATE试验正在进行，预计2025年下半年公布初步概念验证数据[1][2][3] - 新型驱动蛋白项目预计2025年年中提名开发候选药物，2026年上半年提交新药研究申请（IND）[1][2][8] 业务目标 - 公司致力于解决14% - 17%癌症患者中观察到的致癌基因扩增问题[6] 公司人事变动 - 2025年2月公司任命Robert Doebele为首席医疗官[4]

文章核心观点 Boundless Bio公布2024财年第四季度和全年财务业绩及业务亮点，公司在研项目推进，现金状况可支撑运营至2027年，有望为致癌基因扩增癌症患者提供变革性疗法 [1] 研究与开发亮点及即将到来的里程碑 - BBI - 355是新型口服CHK1抑制剂，用于治疗致癌基因扩增癌症，1/2期POTENTIATE试验正在招募患者，预计2025年下半年公布初步概念验证数据 [1][2][6] - 公司正在推进针对ecDNA分离和遗传的新型驱动蛋白项目，预计2025年年中选定开发候选药物，2026年上半年提交新药研究申请（IND） [1][2][6] 近期公司亮点 - 2025年2月，公司任命Robert Doebele博士为首席医疗官，其曾在Rain Oncology领导多个肿瘤项目开发 [4] 2024年第四季度和全年财务结果 现金状况 - 截至2024年12月31日，现金、现金等价物和短期投资总计1.521亿美元 [7][13] 研发费用 - 2024年第四季度研发费用为1330万美元，全年为5530万美元，2023年同期分别为1040万美元和4260万美元 [7][13] 一般及行政费用 - 2024年第四季度一般及行政费用为500万美元，全年为1800万美元，2023年同期分别为340万美元和1220万美元 [7][13] 净亏损 - 2024年第四季度净亏损为1640万美元，全年为6540万美元，2023年同期分别为1210万美元和4940万美元 [8][13] 公司简介 - Boundless Bio是临床阶段肿瘤公司，致力于通过靶向ecDNA开发癌症疗法，以满足致癌基因扩增肿瘤患者的未满足需求，公司正在开发首个ecDNA导向治疗候选药物BBI - 355，并利用Spyglass平台推进其他ecDTx项目的临床前开发和发现 [9]

SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Leerink’s Global Healthcare Conference. A fireside chat session is scheduled for Wednesday, March 12, 2025, in Miami, FL, at 11:20 a.m. ET. A live and a ...

- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers -SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert (“Bob”) Doebele, M.D., Ph.D., has been appointed as Chi ...

Wall Street was off to a volatile start in 2025, following a steep sell-off in the final weeks of 2024. Notably, the small-cap Russell 2000 Index fell 8.4% in December, marking its worst month since September 2022. The index is up 0.4% in the initial week of 2025. Smooth trading is likely to continue given the “January Effect," which refers to a seasonal increase in stock prices during the month. For investors looking to capitalize on this opportunity, small-cap stocks that are down in double-digits or in h ...

With the launch of the "Classic or Nothing" campaign, Tanqueray will celebrate its legacy alongside other timeless icons across culture that have stood the test of time. The new campaign champions individuals who dare to swim against the tide and audaciously choose the classics, embracing quality over trend. It's a bold declaration that some things—like a dirty martini with Tanqueray's award-winning London Dry Gin—never go out of style. The social-first campaign introduces a fresh, vibrant look that propels ...

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial  Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development milestones for third ecDTx program Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, stepping down; James L. Freddo, M.D., to serve as Interim Chief Medical Officer SAN DIEGO, Dec. 12 ...

A downtrend has been apparent in Boundless Bio, Inc. (BOLD) lately with too much selling pressure. The stock has declined 19.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators ...

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Piper Sandler’s 36th Annual Healthcare Conference. A fireside chat session is scheduled for Wednesday, December 4, 2024, in New York, NY, at 3:30 p.m. E ...

Our second ecDTx, BBI-825, is a novel, oral, selective small molecule inhibitor of ribonucleotide reductase (RNR) being studied in the ongoing first-in-human, Phase 1/2 STARMAP clinical trial in colorectal cancer patients with BRAF V600E or KRAS G12C mutations and resistance oncogene amplifications (clinicaltrials.gov identifier NCT06299761). Multiple dose levels have been completed in the single-agent, dose-escalation portion of the trial and, to date, BBI-825 has demonstrated oral bioavailability and has ...